Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [0.03%]
结直肠癌局部病变：诊断、治疗和随访欧洲肿瘤内科学会临床实践指南
R-D Hofheinz,E Fokas,L Benhaim et al.
R-D Hofheinz et al.
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0) [0.03%]
ESMO临床获益规模版本2.0(ESMO-MCBS v2.0)
N I Cherny,S F Oosting,U Dafni et al.
N I Cherny et al.
Background: The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated tool to assess the magnitude of clinical benefit from new cancer therapies, with planned updates based upon recognition of new needs and ...
Letter to the editor 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by F. André et al [0.03%]
写给编辑部的信“关于在人类表皮生长因子受体2（HER2）阳性乳腺癌脑转移患者中对曲妥珠单抗德鲁克斯进行汇总分析”由弗朗索瓦·安德烈等人撰写
Yi Liu,Chuanhao Zhang,Yi Liu
Yi Liu
Letter to the Editor - Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy - PENELOPE-B [0.03%]
写给编辑室：Penelope-B试验的最终生存分析——晚期HR+/HER2-乳腺癌新辅助化疗后残留病灶患者的Palbociclib对比安慰剂治疗研究
Taha Koray Sahin,Deniz Can Guven
Taha Koray Sahin
Spatio-temporal T cell tracking for personalized TCR-T designs in childhood cancer [0.03%]
儿童癌症中用于个性化TCR-T设计的时空T细胞追踪技术
I Sentís,J L Melero,A Cebria-Xart et al.
I Sentís et al.
Background: Immune checkpoint inhibition (ICI) has revolutionized oncology, offering extended survival and long-term remission in previously incurable cancers. While highly effective in tumors with high mutational burden,...
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304) [0.03%]
循环脂质谱系、前列腺特异性膜抗原人源化单克隆抗体达雷妥尤单抗与转移性激素敏感型前列腺癌患者的临床转归的相关性：ANZUP 1304 III期随机对照试验的事后分析
H-M Lin,T Scheinberg,N Portman et al.
H-M Lin et al.
Background: Enzalutamide significantly improves overall survival (OS) of patients with metastatic hormone- sensitive prostate cancer (mHSPC). However, ∼10% of patients will die within 2 years. PCPro is a plasma lipid pan...
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study [0.03%]
帕博利尤单抗联合恩扎卢卡马比和雄激素剥夺治疗与安慰剂联合恩扎卢卡马比和雄激素剥夺治疗转移性激素敏感型前列腺癌的疗效：一项随机、双盲、III期KEYNOTE-991研究
C Gratzke,M Özgüroğlu,A Peer et al.
C Gratzke et al.
Background: Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double...
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study [0.03%]
帕博利尤单抗联合恩扎卢胺对比安慰剂联合恩扎卢胺治疗化疗初治的转移性去势抵抗性前列腺癌：Ⅲ期随机双盲KEYNOTE-641研究
J N Graff,M Burotto,P C Fong et al.
J N Graff et al.
Background: Established first- and second-line standard-of-care treatment options (abiraterone, enzalutamide, taxane chemotherapy) are available for patients with metastatic castration-resistant prostate cancer (mCRPC), b...
A Constantinidou,R L Jones
A Constantinidou
Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study [0.03%]
关于电子鼻分析呼出气检测肺癌的多中心前瞻性外部验证研究的信件
Juntong Liu,Yan Shi,Yufeng Yang
Juntong Liu